OverviewChartTechnicalNews
Derivatives
TraderScreen

Genfit SA/  FR0004163111  /

Euronext - Paris
03/06/2024  12:04:55 Chg. +0.080 Volume Bid12:05:32 Ask12:05:00 High Low
4.800EUR +1.69% 403,925
Turnover: 1.91 mill.		 4.770Bid Size: 425 4.800Ask Size: 657 4.900 4.560
GlobeNewswire 29/05 GENFIT to Present Latest ACLF Research at EASL Congress™ 2024
GlobeNewswire 22/05 GENFIT: May 22, 2024 Combined Shareholders Meeting Results
GlobeNewswire 14/05 GENFIT Reports First Quarter 2024 Financial Information
GlobeNewswire 25/04 GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)
GlobeNewswire 15/04 GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents
GlobeNewswire 05/04 GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report ...
GlobeNewswire 04/04 GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire 29/02 GENFIT Announces Revenues and Cash Position as of December 31, 2023
GlobeNewswire 15/01 GENFIT Announces 2024 Financial Calendar  
GlobeNewswire 08/12/2023 GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangit...
GlobeNewswire 07/12/2023 Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the trea...
GlobeNewswire 07/12/2023 Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the trea...
GlobeNewswire 06/12/2023 GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a...
GlobeNewswire 16/11/2023 GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023
GlobeNewswire 13/11/2023 Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaki...
GlobeNewswire 13/11/2023 GENFIT: Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as lat...
GlobeNewswire 09/11/2023 GENFIT Reports Third Quarter 2023 Financial Information
GlobeNewswire 02/11/2023 GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023
GlobeNewswire 26/09/2023 GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Te...
GlobeNewswire 20/09/2023 GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire 05/09/2023 GENFIT to Participate in Upcoming Investor Conferences
GlobeNewswire 28/02/2022 GENFIT Announces Solid Revenues and Cash Position as of December 31, 2021
GlobeNewswire 24/01/2022 GENFIT: 2022 Financial Calendar
GlobeNewswire 17/12/2021 On heels of global strategic partnership announced today, GENFIT acquires rights to novel asset
GlobeNewswire 17/12/2021 GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset...